Elevated plasma non-esterified fatty acid levels and insulin secretion in non-diabetic relatives of type 2 diabetic patients
Article first published online: 20 DEC 2001
Volume 55, Issue 3, pages 349–355, September 2001
How to Cite
Butler, T. J., Barriocanal, L. A. and Walker, M. (2001), Elevated plasma non-esterified fatty acid levels and insulin secretion in non-diabetic relatives of type 2 diabetic patients. Clinical Endocrinology, 55: 349–355. doi: 10.1046/j.1365-2265.2001.01340.x
- Issue published online: 20 DEC 2001
- Article first published online: 20 DEC 2001
- (Received 9 October 2000; accepted 20 March 2001)
OBJECTIVE High non-esterified fatty acid (NEFA) levels impair glucose-stimulated insulin secretion from islets derived from non-diabetic Zucker rats that are genetically predisposed to diabetes. We therefore examined the effect of elevated plasma NEFA levels on insulin secretion in non-diabetic first-degree relatives of type 2 diabetic patients who are at increased risk of developing diabetes.
SUBJECTS AND STUDY DESIGN Normal glucose tolerant relatives (n = 9) and control subjects with no family history of diabetes were pair-matched for age, sex, body mass index (BMI), insulin sensitivity and early insulin response during an oral glucose tolerance test (OGTT). Plasma NEFA levels were raised from 0 to 340 minutes by the infusion of 20% Intralipid and heparin. From 180 minutes, insulin secretion rates (IRSs) were assessed by stepped low-dose glucose infusion.
RESULTS The mean (geometric mean ± 95% CI) NEFA levels were comparable between relatives and control subjects (2·7 [2·1–3·6] and 2·1 [1·7–2·7] mmol/l, paired analysis, NS). Similarly, plasma glucose levels achieved at each glucose infusion step were comparable between the groups. However, there were no significant differences between the groups for ISR throughout the study.
CONCLUSIONS Sustained elevation of plasma non-esterified fatty acid levels does not decrease insulin secretion in non-diabetic relatives of type 2 diabetic patients, and is therefore unlikely to be important in the development of the impaired pancreatic beta-cell function in type 2 diabetes mellitus.